(Q38363617)

2 September 2017

1 reference

title

Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy (English)

1 reference

2 September 2017

1 reference

Robert S Rosenson

1

1 reference

2 September 2017

Michael H Davidson

2

1 reference

2 September 2017

Ngoc-Anh Le

3

1 reference

2 September 2017

Jaime Burkle

4

1 reference

2 September 2017

Ray Pourfarzib

5

1 reference

2 September 2017

publication date

1 February 2015

1 reference

Cardiovascular Drugs and Therapy

2 September 2017

published in

1 reference

2 September 2017

volume

29

1 reference

2 September 2017

issue

1

1 reference

2 September 2017

page(s)

41-50

1 reference

Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Lipids, risk factors and ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Cholesteryl ester transfer protein and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Biological activities of HDL subpopulations and their relevance to cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Unraveling the complexities of the HDL lipidome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Quantification of HDL particle concentration by calibrated ion mobility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

The paradox of dysfunctional high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoproteins, platelets and the pathogenesis of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein heterogeneity and function in reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Beginning to understand high-density lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of diet on high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of wheat and oat-based whole grain foods on serum lipoprotein size and distribution in overweight middle aged people: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Acute changes in lipoprotein subclasses during exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein particle size and concentration and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

HDL cholesterol efflux capacity and incident cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6567-0

10.1007/S10557-014-6567-0

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference